Optimizerx Corp Stock Price, News & Analysis

OptimizeRx (NASDAQ: OPRX), a healthcare technology solutions provider, has announced its participation in four major investor conferences in May and June 2025. The company will attend:

- B. Riley Securities 25th Annual Investor Conference (May 22) in Marina del Rey, featuring 1x1 meetings and a fireside chat
- Stifel 2025 Boston Cross Sector 1x1 Conference (June 3) at InterContinental Boston
- 45th Annual William Blair Growth Stock Conference (June 5) at Loews Chicago Hotel
- The Citizens Medical Devices and Healthcare Services Forum (June 17) at Boston Harbor Hotel

The latter three events will consist of one-on-one meetings with institutional investors.

OptimizeRx (NASDAQ: OPRX) reported strong Q1 2025 financial results with revenue increasing 11% year-over-year to $21.9 million. The company's gross profit grew 9% to $13.3 million, while GAAP net loss improved to $(2.2) million from $(6.9) million in Q1 2024. Non-GAAP net income reached $1.5 million or $0.08 per diluted share.

Notably, OptimizeRx has increased its full-year 2025 guidance, projecting revenue between $101-106 million and adjusted EBITDA between $13-15 million. The company's performance metrics show strong momentum, with year-to-date contracted revenue up over 20% compared to last year. Additionally, OptimizeRx has successfully converted over 5% of expected 2025 sales into subscription-based revenue streams.

OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has scheduled its first quarter 2025 earnings conference call for Monday, May 12, 2025, at 4:30 p.m. Eastern Time. The company will release its financial results for the period ended March 31, 2025, via press release before the call.

The conference call will include a management presentation followed by a Q&A session. Investors can join through multiple channels including toll-free (1-844-825-9789) and international (1-412-317-5180) numbers. A webcast option is also available, and the replay will be accessible for 12 months through the company's investor relations website.

OptimizeRx (Nasdaq: OPRX) has announced plans to appoint a new independent director to its Board during the second half of 2025, continuing its board refreshment initiative. This appointment will mark the third new director since 2020, following Catherine Klema (2024) and Gregory D. Wasson (2020) additions.

The company, which specializes in healthcare technology solutions connecting life sciences companies with healthcare professionals and patients, is seeking candidates with relevant expertise to complement current Board members and support the company's strategy execution. The Board currently consists of five directors.

Board Chairperson Lynn Vos highlighted the company's progress under new CEO Steve Silvestro, focusing on building market share and driving profitable revenue growth. The company aims to address key pharma challenges including digital brand visibility, reducing script abandonment rates, enhancing point-of-care interoperability, and supporting specialty medications transition.

OptimizeRx (OPRX) reported strong Q4 2024 results with revenue increasing 14% year-over-year to $32.3 million. Q4 gross profit grew 23% to $22.0 million with a 68% margin. Full-year 2024 revenue reached $92.1 million, up 29% from 2023.

The company doubled its DAAP deals from 24 in 2023 to 48 in 2024. Q4 non-GAAP net income was $5.5 million ($0.30 per diluted share), while Adjusted EBITDA increased 53% to $8.8 million. Full-year GAAP net loss was $(20.1) million.

Looking ahead, OptimizeRx provided 2025 guidance with expected revenue of at least $100 million and Adjusted EBITDA of at least $12 million. The company is transitioning DAAP customers to a subscription-based model for data services to improve margins and reduce business cyclicality.

OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has confirmed receiving a notice of nominations from stockholder Whetstone Capital Advisors, . The notice indicates Whetstone's intention to nominate two candidates for election to the OptimizeRx Board of Directors at the company's 2025 Annual Meeting of Stockholders.

The OptimizeRx Board will review the nominations and provide their formal recommendation in the upcoming definitive proxy statement, which will be filed with the SEC and distributed to eligible voting stockholders. The company emphasized that no stockholder action is currently required, and the 2025 Annual Meeting date has not yet been scheduled.

OptimizeRx (Nasdaq: OPRX) has appointed Steve Silvestro as its new Chief Executive Officer, effective March 10, 2025. Silvestro, who has been with the company since 2019, brings over 20 years of experience in health technology and services.

Previously serving as Chief Commercial Officer, President, and interim CEO, Silvestro was unanimously selected by the independent Directors following a rigorous search process. During his tenure at OptimizeRx, he has been important in transforming the company from a single-solution digital marketing provider to an industry leader with omnichannel capabilities.

The new CEO's strategic priorities include:

• Focusing on operational excellence and customer satisfaction
• Expanding value proposition with pharmaceutical companies
• Increasing recurring revenue model
• Driving towards becoming a Rule of 40 company
• Creating new opportunities for profitable revenue growth

OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has scheduled its Fourth Quarter and Full Year 2024 financial results conference call for March 12, 2025, at 8:30 a.m. ET. The company will release its financial results for the quarter ended December 31, 2024, via press release before the conference call. Management will host the call followed by a Q&A session. A replay will be accessible for 12 months through the Investors section of the OptimizeRx website.